Uridine Diphosphate-glucose Dehydrogenase as a Prostate Cancer Biomarker Candidate
Advisor Information
Paul Davis
Location
UNO Criss Library, Room 232
Presentation Type
Oral Presentation
Start Date
7-3-2014 3:15 PM
End Date
7-3-2014 3:30 PM
Abstract
Prostate cancer is the most common cancer in men. Early detection and diagnosis could potentially lead to a higher cancer survival rate. In this study, the expression of the enzyme uridine diphosphate-glucose dehydrogenase was examined as a possible biomarker, or measurable characteristic, for aggressive prostate cancer. The development of a specific and sensitive biomarker for the initial prostate biopsy would provide information for diagnosis and serve as a guide for additional biopsies. Uridine diphosphate-glucose dehydrogenase is an enzyme that catalyzes the oxidation of uridine diphosphate-glucose, yielding uridine diphosphate- glucuronic acid. Uridine diphosphateglucuronic acid is a precursor in synthesizing glycosaminoglycans and proteoglycans, hyaluronan, and other molecules. These molecules have been found to promote the progression of prostate cancer. We determined the levels of the enzyme uridine diphosphate-glucose dehydrogenase using quantitative fluorescence imaging analysis by selective binding of a polyclonal antibody with an attached fluorescent tag to the enzyme. Fixed tissue samples were embedded in paraffin-wax, added to slides with antibody incubation, imaged. The image was analyzed by quantifying the signal of the tagged enzyme and comparing the data between pairs of normal appearing prostate biopsies and age-matched noncancerous controls. Previous research has shown significant difference between the levels of Uridine diphosphate-glucose dehydrogenase in cancerous prostate acini compared to non- cancerous prostate acini. These results support the suggestion that the levels of Uridine diphosphate-glucose dehydrogenase found in prostate cancer may serve as a biomarker for the likelihood of prostate cancer disease progression.
Uridine Diphosphate-glucose Dehydrogenase as a Prostate Cancer Biomarker Candidate
UNO Criss Library, Room 232
Prostate cancer is the most common cancer in men. Early detection and diagnosis could potentially lead to a higher cancer survival rate. In this study, the expression of the enzyme uridine diphosphate-glucose dehydrogenase was examined as a possible biomarker, or measurable characteristic, for aggressive prostate cancer. The development of a specific and sensitive biomarker for the initial prostate biopsy would provide information for diagnosis and serve as a guide for additional biopsies. Uridine diphosphate-glucose dehydrogenase is an enzyme that catalyzes the oxidation of uridine diphosphate-glucose, yielding uridine diphosphate- glucuronic acid. Uridine diphosphateglucuronic acid is a precursor in synthesizing glycosaminoglycans and proteoglycans, hyaluronan, and other molecules. These molecules have been found to promote the progression of prostate cancer. We determined the levels of the enzyme uridine diphosphate-glucose dehydrogenase using quantitative fluorescence imaging analysis by selective binding of a polyclonal antibody with an attached fluorescent tag to the enzyme. Fixed tissue samples were embedded in paraffin-wax, added to slides with antibody incubation, imaged. The image was analyzed by quantifying the signal of the tagged enzyme and comparing the data between pairs of normal appearing prostate biopsies and age-matched noncancerous controls. Previous research has shown significant difference between the levels of Uridine diphosphate-glucose dehydrogenase in cancerous prostate acini compared to non- cancerous prostate acini. These results support the suggestion that the levels of Uridine diphosphate-glucose dehydrogenase found in prostate cancer may serve as a biomarker for the likelihood of prostate cancer disease progression.